[{"abstract": "The company\u2019s rejection of Pfizer\u2019s latest offer disappointed some investors, while others said the deal was not in AstraZeneca\u2019s best interest.", "web_url": "https://dealbook.nytimes.com/2014/05/20/large-shareholder-urges-astrazeneca-to-continue-talks-with-pfizer/", "snippet": "The company\u2019s rejection of Pfizer\u2019s latest offer disappointed some investors, while others said the deal was not in AstraZeneca\u2019s best interest.", "lead_paragraph": "Updated, 7:20 p.m. LONDON \u2014 Some of AstraZeneca\u2019s largest shareholders were publicly split Tuesday on whether the company should continue merger discussions with Pfizer.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/21/business/ASTRA/ASTRA-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/21/business/ASTRA/ASTRA-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/21/business/ASTRA/ASTRA-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/21/business/ASTRA/ASTRA-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/21/business/ASTRA/ASTRA-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/21/business/ASTRA/ASTRA-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/21/business/ASTRA/ASTRA-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer\u2019s Latest Offer Divides Some of Largest Shareholders in AstraZeneca", "kicker": "DealBook", "content_kicker": null, "print_headline": "Pfizer\u2019s Latest Offer Divides Some of Largest Shareholders in AstraZeneca ", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Stocks and Bonds", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}, {"name": "glocations", "value": "Great Britain", "rank": 6, "major": "N"}], "pub_date": "2014-05-20T13:47:42+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Chad Bray", "person": [{"firstname": "Chad", "middlename": null, "lastname": "Bray", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/e5541058-536a-5534-bfe8-40fbce2e567e", "word_count": 684, "uri": "nyt://article/e5541058-536a-5534-bfe8-40fbce2e567e"}, {"abstract": "An apparent loophole in Britain\u2019s takeover code means Pfizer could offer a higher price for AstraZeneca, even after declaring that its earlier pitch was \u201cfinal,\u201d says Christopher Hughes of Reuters Breakingviews.", "web_url": "https://dealbook.nytimes.com/2014/05/20/loophole-offers-pfizer-a-risky-way-back-into-a-deal/", "snippet": "An apparent loophole in Britain\u2019s takeover code means Pfizer could offer a higher price for AstraZeneca, even after declaring that its earlier pitch was \u201cfinal,\u201d says Christopher Hughes of Reuters Breakingviews.", "lead_paragraph": "Pfizer has a risky way back into a deal with AstraZeneca. An apparent loophole in Britain\u2019s takeover code means that the American pharmaceutical giant could offer the 58.85 pounds-a-share demanded by Astra for a recommendation, even after declaring that the earlier \u00a355-a-share pitch was \u201cfinal.\u201d", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg", "height": 900, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 900}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg", "height": 1024, "width": 683, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg", "height": 2048, "width": 1366, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Loophole Offers Pfizer a Risky Way Back Into a Deal", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 4, "major": "N"}], "pub_date": "2014-05-20T17:29:07+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Christopher Hughes", "person": [{"firstname": "Christopher", "middlename": null, "lastname": "Hughes", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c88d558c-9fc7-54c8-8fac-f4ce5d8dc5bd", "word_count": 339, "uri": "nyt://article/c88d558c-9fc7-54c8-8fac-f4ce5d8dc5bd"}]